A detailed history of Wellington Management Group LLP transactions in Nkarta, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 216,341 shares of NKTX stock, worth $530,035. This represents 0.0% of its overall portfolio holdings.

Number of Shares
216,341
Previous 173,306 24.83%
Holding current value
$530,035
Previous $1.02 Million 4.59%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.52 - $8.0 $194,518 - $344,280
43,035 Added 24.83%
216,341 $977,000
Q2 2024

Aug 13, 2024

BUY
$5.27 - $10.82 $231,521 - $475,344
43,932 Added 33.96%
173,306 $1.02 Million
Q1 2024

May 15, 2024

BUY
$5.59 - $15.71 $723,200 - $2.03 Million
129,374 New
129,374 $1.4 Million
Q1 2023

May 12, 2023

BUY
$3.37 - $6.3 $9,752 - $18,232
2,894 Added 4.34%
69,571 $246,000
Q4 2022

Feb 13, 2023

SELL
$5.14 - $14.35 $10,788 - $30,120
-2,099 Reduced 3.05%
66,677 $399,000
Q3 2022

Nov 14, 2022

BUY
$12.27 - $18.39 $501,806 - $752,095
40,897 Added 146.69%
68,776 $905,000
Q1 2022

May 16, 2022

BUY
$8.66 - $14.99 $13,457 - $23,294
1,554 Added 5.9%
27,879 $317,000
Q4 2021

Feb 11, 2022

BUY
$12.79 - $26.88 $336,696 - $707,616
26,325 New
26,325 $404,000
Q2 2021

Aug 16, 2021

SELL
$23.94 - $36.68 $11.7 Million - $17.9 Million
-489,000 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$31.33 - $59.61 $3.56 Million - $6.77 Million
-113,503 Reduced 18.84%
489,000 $16.1 Million
Q4 2020

Feb 12, 2021

BUY
$27.03 - $75.62 $4.83 Million - $13.5 Million
178,745 Added 42.18%
602,503 $37 Million
Q3 2020

Nov 16, 2020

BUY
$23.52 - $47.9 $9.97 Million - $20.3 Million
423,758 New
423,758 $12.7 Million

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $119M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.